Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphoma.

Lucie ObericFaustine DelzorCaroline ProtinSophie PerriatCamille LaurentAnaïs GrandJean Marie CanongeCécile BorelMartin GauthierLoïc YsebaertFlorent Puisset

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)

Our current study shows that Bv used in combination with chemotherapy provides a high CRR and thereby allows SCT in R/R PTCL. The use of Bv treatments in this setting warrants further investigation.

Keyphrases

hodgkin lymphoma
lps induced
lipopolysaccharide induced
acute lymphoblastic leukemia
acute myeloid leukemia
diffuse large b cell lymphoma
squamous cell carcinoma
inflammatory response
locally advanced